

Living with **ocular** (eye-only) **myasthenia gravis?**

The MyVision Study is a clinical research study that is hoping to better understand eye-only myasthenia gravis (oMG) and its symptoms while advancing scientific research at the same time. The aim of the study is to learn how well the study drug works (efficacy) and what side effects people experience while taking it (safety).

Ocular myasthenia gravis (oMG)

oMG is a form of myasthenia gravis (MG) that causes weakness in the muscle around the eyes, leading to double vision, droopy eyelids, and difficulty looking in different directions.

Introducing the MyVision Study

UCB, a global biopharma company, is conducting a phase 3 research study, which will be assessing a study drug in those living with oMG. The study is testing a study drug currently approved for the treatment of generalized myasthenia gravis but not oMG.

Who can join the MyVision Study?

You may be able to join if you:

- Are at least 18 years of age
- Have been diagnosed with oMG by a doctor
- Are **not** experiencing weakness in other muscles in your body such as your face, throat, arms, and/or legs

The oMG diagnosis should be supported by one of the following:

- A blood test showing specific antibodies (AChR or MuSK), **or**
- If no antibodies are found, then nerve tests (RNS or SFEMG) **plus at least one of these**:
  - Positive "ice test"
  - Past positive edrophonium (also known as Tensilon) test
  - Improvement in eye symptoms after treatments like IVIg, plasma exchange, or medications like acetylcholinesterase inhibitors, corticosteroids, or other immunosuppressive medications

If you don't know whether you meet these criteria or not, please speak to the study team; they will be happy to help you find out or tell you more about what these tests are. Other requirements need to be met to join the MyVision Study, which the study team at the study centre will be able to discuss with you.

If you qualify and decide to join, you will get:

- The study drug or a placebo
- Close medical care and follow-up throughout the study

Reimbursement for travel expenses and other study-related expenses may be provided.

MyVision

What should I expect in the MyVision Study?

Study participants will be randomly assigned (like flipping a coin where there's a 50% chance of getting heads and a 50% chance of getting tails) to a treatment group, where they will either receive the study drug or a placebo. A placebo looks the same as the study drug but contains no medicinally-active ingredients. The study drug or placebo is given under the skin (injected subcutaneously, also known as an SC injection).

The study lasts 19 weeks in total with 13 visits to the study centre. The study has the following 3 periods:

- **Screening Period:** Up to 6 weeks
- **Treatment Period:** 6 weeks (weekly doses of the study drug or a placebo)
- **Observation Period:** 4 to 7 weeks, depending on whether you choose to enter the open-label extension (OLE) study and whether additional treatment is needed

Can I remain on my current medications?

With few exceptions, you will be able to remain on your current medications for your eyes, but the dose and frequency must remain unchanged for a 6-week period (during the treatment period). If you have any questions or need clarification, please feel free to reach out to the study team.

What happens if my symptoms get worse?

During the study, if your symptoms get worse, your doctor and you may decide to add additional treatment, which could include starting corticosteroids or increasing their dose, IVIg (intravenous immunoglobulin), or PLEX (plasma exchange).

Can I still see my neurologist or other physician?

If you are already seeing a neurologist or other physician for your oMG, we encourage you to speak to them about joining the study. You can keep seeing your regular neurologist or other physician while you're in the study.

What are the potential risks/benefits of joining the study?

The MyVision Study is being done to learn more about the study drug. Because this drug is still being researched, there is no guarantee that taking part will help you. All medicines can cause side effects. One of the main goals of this study is to watch for any side effects in study participants. Before you decide to join, you will get detailed information about the side effects that have already been seen in earlier studies with this study drug. If you have any concerns or questions about possible side effects, please talk to the study team—they are here to help you.

MyVisionXT

You may have the opportunity to join an extension study called MyVisionXT. In this study, all participants will receive the study drug—there is no chance of a placebo being given. You can receive more information about the extension study by asking the study team.

Thank you

We appreciate your interest in the MyVision Study, as the most important people in clinical research are volunteers. Without people like you, clinical studies could not take place.

For more information and to see if you qualify, you can visit myvisionstudy.com or contact:

MyVision

Inspired by patients. Driven by science.

MG0038_Joint-FS_v1.0_US Eng_15JAN2026_English (Canada)_31MAR2026